Full-Time
Customer Success Manager
Updated on 9/3/2026
Revvity
1,001-5,000 employees
Translational multi-omics and diagnostics provider
No salary listed
Remote in UK
Remote
Remote within the United Kingdom, with travel up to approximately 20% for customer engagements.
Bachelor's
 Customer Experience & Support (1) |
|---|
Get referred to Revvity
See people who can refer or advise you
- A bachelor's degree in Chemistry, Biology, Chemical Engineering, Materials Science, or a related scientific discipline, or equivalent relevant experience.
- At least 5 years of experience in a software environment, preferably with enterprise or software-as-a-service platforms.
- At least 3 years of customer-facing experience in Customer Success, Professional Services, Consulting, or Presales roles.
- Ability to engage effectively with technical and scientific users at multiple organizational levels.
- Strong analytical, troubleshooting, and problem-solving skills, including the ability to navigate complex customer environments.
- Willingness to travel up to approximately 20% as required to support customer engagements.
- Serve as the primary customer point of contact for post-sale success and act as a trusted business and technical advisor to customer stakeholders across scientific, technical, and leadership roles.
- Track and monitor solution adoption, license utilization, and usage trends, proactively identifying risks and opportunities to increase customer value.
- Drive customers toward best-practice usage and ensure a positive user experience and measurable outcomes from Revvity Signals platforms.
- Coordinate Revvity Signals' response to customer needs by involving Product, Services, Support, Sales, and Cloud teams as required to drive outcomes.
- Partner with Professional Services to oversee implementations, enhancements, and project delivery, ensuring engagement health and accountability across Revvity Signals and the customer.
- Collaborate with Product Management on roadmap discussions, feature feedback, enhancement requests, and defect prioritization.
- Support Account Management and Sales by identifying growth opportunities, expansion use cases, and renewal risks while maintaining clear ownership boundaries.
- Ensure consistent, proactive communication with customers and internal stakeholders regarding engagement status, risks, and priorities.
- Experience supporting life sciences, pharmaceutical, biotechnology, or industrial chemical customers.
- Proven ability to collaborate across cross-functional, time-sensitive teams.
- Strong written and verbal communication skills, including the ability to deliver compelling customer presentations.
Revvity provides health science solutions that span the full journey from discovery to development and from diagnosis to cure. It offers translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, and informatics, all delivered as integrated workflows and expert services. The company differentiates itself with an end-to-end platform that combines omics, imaging, biomarkers, and data analytics with specialized support to speed development. Its goal is to turn previously impossible healthcare outcomes into achievable results, advancing discovery, development, diagnosis and patient care.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2023
Get referred to Revvity
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $730 million; adjusted margins hit 28.9%.
- Revvity raised 2026 guidance to $2.83-$2.86 billion revenue and $5.30-$5.40 EPS.
- SuperFlex launched August 10, 2026, targeting underserved lower-volume prenatal labs immediately.
What critics are saying
- Revvity is closing Boston and Lawrence sites, with 282 Massachusetts WARN layoffs through 2026.
- China immunodiagnostics, about 6% of 2025 revenue, exits by end-2027.
- T-SPOT A201 depends on 2027 regulatory approval; failure weakens infectious-disease growth.
What makes Revvity unique
- Revvity bundles SuperFlex, T-SPOT A201, and LifeCycle into decentralized workflows.
- Revvity's 2026 portfolio spans prenatal screening, TB automation, and biopharma informatics.
- ACD/Labs acquisition and Signals software deepen Revvity's discovery-to-diagnosis platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Employee Stock Purchase Plan
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%Revvity has launched SuperFlex, a compact prenatal screening system designed for small and mid-sized laboratories. The CE-IVDR-certified automated immunoassay instrument will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. The benchtop immunoanalyser processes up to 60 tests per hour and delivers initial results in 14 minutes. It supports preeclampsia screening and prenatal testing using chemiluminescence immunoassay technology with 24 sample positions. SuperFlex aims to address financial and operational barriers in lower-volume testing environments by offering lower instrument costs, reduced maintenance expenses, and no reagent wastage. The platform integrates with Revvity's LifeCycle software. Revvity shares gained 1.6% following the announcement and have risen 21.8% year-to-date. The company has a market capitalisation of $12.91 billion.
Revvity has launched the SuperFlex prenatal screening system, a compact, CE-IVDR certified immunoassay instrument designed for laboratories and clinics with lower-volume workflows. The system tests for preeclampsia, which affects 2% to 8% of pregnancies globally. The platform features affordable instrument costs with annual maintenance, no reagent wastage at low volumes, and delivers results in as little as 14 minutes per test. It includes a test menu for first- and second-trimester biochemical prenatal screening. The system will initially be available in markets accepting CE-marked instruments, with Asia-Pacific expansion planned for late 2026. Revvity reported 2025 revenue of $2.9 billion and employs approximately 11,000 people.
Upstart, an AI-powered lending platform, stands out as a buy opportunity among profitable stocks, according to StockStory's analysis. The company uses machine learning to assess borrower risk for various loan types. Upstart's loan originations surged 54.3% over the past year, enabling increased fee collection and expansion into new markets like credit cards. The company's revenue is expected to grow 30.6% over the next 12 months, with free cash flow anticipated to turn positive next year. Meanwhile, StockStory advises caution on Revvity and Northern Trust. Revvity's sales declined 10.6% annually over five years, whilst Northern Trust's 6.9% annual revenue growth lagged behind financial peers. Both companies face headwinds despite maintaining profitability, with earnings pressures and market share concerns affecting their outlooks.
Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing Business Wire
Revvity reported second quarter 2026 revenue of $730 million, with pro forma revenue of $711 million representing 4% growth and 3% organic growth. The company posted GAAP earnings per share from continuing operations of $0.48, while adjusted EPS reached $1.41. The company announced a definitive agreement to divest its China Immunodiagnostics business, which accounted for approximately 6% of total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to regulatory approvals. Adjusted operating profit margin improved to 28.9%, up from 26.6% in the prior year period. GAAP operating income included $16 million in tariff-related refunds. Revvity raised its full-year guidance following the results.